nach oben

Drugs in R&D

Erschienen in:

01.01.2003 | Adis R&D Profile

Emtricitabine

524W91, BW524W91, Coviracil®, FTC

Erschienen in: Drugs in R&D | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Excerpt

Emtricitabine [524W91, BW524W91, FTC, Coviracil®], an oxathiolane nucleoside with a resistance profile similar to lamivudine, was discovered at Emory University in the US.¹ It is a nucleoside reverse transcriptase inhibitor (NRTI) with demonstrated potent activity against HIV and hepatitis B virus (HBV). Emtricitabine was originally licensed to Glaxo Wellcome. The license was subsequently taken over by Triangle Pharmaceuticals, a company formed by a group of researchers and executives from Glaxo Wellcome. Clinical evaluation of emtricitabine was re-initiated by Triangle. …

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Triangle Pharmaceuticals Inc. Triangle Pharmaceuticals, Inc. Announces Data Safety Monitoring Board’s Recommendation to Unblind Coviracil Pivotal Trial Early. Media Release: 30 Jul 2002. Available from URL: http://www.tripharm.com

Triangle Pharmaceuticals Inc. Triangle Pharmaceuticals, Inc. Announces Final Settlement of Patent Disputes Involving Its Late Stage Drug Candidate Coviracil(R). Media Release: 10 Jun 2002. Available from: URL: http://www.tripharm.com

Painter GR, St Clair M, Ching S, et al. 524W91: anti-HIV, antihepatitis B virus. Drugs of the Future 20: 761–765, Aug 1995

Wang LH, Gardner P, Frick LW, et al. Pharmacokinetics and safety of 524W91 following single oral administration of escalating doses in HIV-infected volunteers. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 24, 17 Sep 1995

Wang LH, Delehanty J, Blum MR, et al. FTC: a potent and selective anti-HIV and anti-HBV agent demonstrating desirable pharmacokinetic characteristics. Clinical Infectious Diseases 27: 999, Oct 1998

Wiznia AA, Wang LH, Rathore MH, Chittick GE, Bakshi SS, et al. An evaluation of the pharmacokinetics and safety of single oral doses of emtricitabine in HIV-infected or exposed children. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 339, 17 Sep 2000

Gish RG, Leung NWY, Wright TL, Trinh H, Lang W, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 46: 1734–1740, Jun 2002PubMedCrossRef

Molina J-M, Ferchal F, Rancinan C, Raffi F, Montana (Agence Nationale de Recherches sur le SIDA 091) Study Group, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 182: 599–602, Aug 2000. Hôpital Saint-Louis, Paris, France

Gish RG, Leung NWY, Schooley RT, Sykes A, Turner F, et al. Emtricitabine: activity against hepatitis B virus in a phase I/II clinical study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy.: 407 (plus poster), 26 Sep 1999. California Pacifica Medical Center, San Francisco, California, USA; Triangle Pharmaceuticals, Durham, North Carolina, USA

10.

Rousseau F, Fang L, Sykes A, Rigney A, Mondou E. Emtricitabine: antiviral efficacy and lack of development of resistance in patients treated 1 year for chronic hepatitis B virus infection parallel results in HIV infection. Antiviral Therapy 6 (Suppl 1): 5, 2001

11.

Zeier M, Sanne I, Van der Berg M, Quinn J, Shaw A. Efficacy and safety of emtricitabine triple combination therapy in HIV- 1 infected treatment-naïve male female patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 346, 22 Sep 2001

12.

Van der Horst C, Benson C, Rodriguez A, Hulett L, Wakeford C, et al. Long-term efficacy and safety of emtricitabine in HIV+ adults switching from a lamivudine containing HAART regimen. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 346, 22 Sep 2001

13.

Saag M, Cahn P, Raffi F, Wolff M, FTC301 Study Team, et al. A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy: Late Breaker Abstracts 8, 27 Sep 2002. Susman E. Emtricitabine shows superiority to stavudine in HIV infections Inpharma. 1363: 9 Nov 2002

14.

Smith SL, Davis MG, Biron K, Lewis S, Cecchi A, et al. Antihepatitis activity in vivo in the naturally infected woodchuck hepatitis model by cis-5-fluoro-1-[2(hydroxy-methyl)-1,3- oxathiolan-5yl] cytosine. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy 191, 1993

15.

Condreay LD, Jansen RW, Powdrill TF, et al. Evaluation of the potent anti-hepatitis B virus agent (-)cis-5-fluoro-1- [2- (hydroxymethyl) -1,3-oxathiolan-5-yl] cytosine in a novel in vivo model. Antimicrobial Agents and Chemotherapy 38: 616–619, Mar 1994PubMedCrossRef

16.

Borroto-Esoda K, Harris J, Shaw A, Wakeford C, Quinn J, et al. Lower incidence of the M184V mutation in patients receiving combination therapy with emtricitabine compared to lamivudine. Antiviral Therapy 6 (Suppl 1): 68, 2001

17.

Triangle Pharmaceuticals Inc. Triangle Pharmaceuticals presents results of a phase I/II clinical study with Coviracil (TM) (emtricitabine), formerly known as FTC in HIV-infected patients. Media Release: [2 pages], 26 Jan 1999

18.

Borroto-Esoda K, Quinn J, Harris J, Shaw A, Hinkle J, et al. Lower incidence of the M184V mutation in ART naïve patients receiving combination therapy with emtricitabine compared to lamivudine, results of a double blind equivalence trial. 1st International Aids Society Conference 331, 8 Jul 2001

19.

Gish RG, Wright TL, Wang C, Cory L, Leung NW, et al. Emtricitabine: results from a 24-week dose-selection trial in patients with chronic HBV infection (FTCB-102). Hepatology 32: 378, Part 2, Oct 2000

20.

Triangle Pharmaceuticals Inc. Triangle Pharmaceuticals, Inc. reports preliminary results for Coviracil (R) (emtricitabine) and clevudine for the treatment of chronic hepatitis B. Media Release: [2 pages], 12 Nov 2001. Available from URL: http://www.tripharm.com

21.

Delehanty J, Rousseau F, Harris J, et al. Anti-HBV activity of FTC in two patients co-infected with HIV and HBV. Clinical Infectious Diseases 27: 975, Oct 1998

Titel: Emtricitabine
524W91, BW524W91, Coviracil®, FTC
Publikationsdatum: 01.01.2003
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 1/2003
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200304010-00007

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Emtricitabine

524W91, BW524W91, Coviracil®, FTC

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2003

Selegiline-Transdermal — Somerset

Profile Summary

Budesonide Hydrofluoroalkane Inhalation — Chiesi

Estradiol-Topical — Novavax

Trabectedin

Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease